BioNTech Acquires Kite’s TCR-T Platform and Manufacturing Facility; Is Kite Pivoting Away from TCR-Ts?
Here is a brief preview of this blast: On Monday, July 19, Gilead (Kite) announced (press release) that BioNTech will acquire Kite’s individualized TCR platform and manufacturing facility in Gaithersburg, MD. Below, Celltelligence provides insights on Gilead’s (Kite) potential approach to treat solid tumors while discussing how BioNTech’s acquisition may quickly advance their pipeline by expanding their US manufacturing footprint.